CSIMarket
 


Mainz Biomed N v   (MYNZ)
Other Ticker:  
 

Cumulative Mainz Biomed N V 's Working Capital Ratio for Trailing Twelve Months Period

MYNZ's Working Capital Ratio for Trailing Twelve Months Period and Current Assets, Current Liabilities growth


Select the Comparisons : Select the Ratio:

MYNZ Working Capital Ratio for Trailing Twelve Months Period

(Dec 31 2022)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Current Liabilities Growth 213.85 % 213.85 % 213.85 % 213.85 % -
Y / Y Current Assets Growth 91.26 % 91.26 % 91.26 % 91.26 % -
Working Capital Ratio for Trailing Twelve Months Period 4.33 4.6 5 5.69 7.11
Total Ranking # 1105 # # # 1091 # 877
Seq. Current Liabilities Growth 0 % 0 % 0 % 213.85 % 0 %
Seq. Current Assets Growth 0 % 0 % 0 % 91.26 % 0 %


Working Capital Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Dec 31 2022
On the trailing twelve months basis Due to unchange in Current Liabilities in the IV. Quarter to $4 millions, average cumulative Working Capital Ratio for Trailing Twelve Months Period decreased to 4.33 below Mainz Biomed N V average Working Capital Ratio for Trailing Twelve Months Period.
Working Capital Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 320 other companies have achieved higher Working Capital Ratio for Trailing Twelve Months Period than Mainz Biomed N V . While overall ranking remained unchanged compare to previous quarter at no. .

What is Working Capital Ratio?
More about MYNZ
Working Capital Ratio MYNZ in the most recent quarter
Working Capital Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 321
Sector # 578
S&P 500 # 1081


Working Capital Ratio for Trailing Twelve Months Period Statistics
High Average Low
7.11 5.71 4.33
(Dec 31 2021)   (Dec 31 2022)




Companies with similar average Working Capital Ratio for Trailing Twelve Months Period for 12 months ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Working Capital Ratio for Trailing Twelve Months Period
Aurinia Pharmaceuticals Inc   11.88 
Chemomab Therapeutics Ltd   11.86 
Cormedix Inc   11.81 
Cytokinetics Incorporated  11.75 
Oncternal Therapeutics Inc   11.70 
Enanta Pharmaceuticals Inc  11.64 
Pepgen Inc   11.49 
Cogent Biosciences Inc   11.47 
Connect Biopharma Holdings Limited  11.45 
Painreform Ltd  11.37 
Metacrine Inc   11.29 
Dianthus Therapeutics Inc   11.23 
Salarius Pharmaceuticals inc   11.17 
Cymabay Therapeutics Inc   11.17 
Aclaris Therapeutics Inc   11.06 
Uniqure N v   11.01 
Vanda Pharmaceuticals Inc   11.00 
Ironwood Pharmaceuticals inc   10.95 
Xilio Therapeutics inc   10.93 
Capricor Therapeutics inc   10.91 
Galecto Inc   10.79 
Ac Immune Sa  10.78 
Histogen Inc   10.76 
Viracta Therapeutics Inc   10.74 
Erasca Inc   10.61 
Hepion Pharmaceuticals inc   10.61 
Oncolytics Biotech Inc   10.46 
Citius Pharmaceuticals Inc   10.44 
Pyxis Oncology Inc   10.39 
Satsuma Pharmaceuticals Inc   10.37 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com